ArticleeLife2022
Early stage NSCLS patients' prognostic prediction with multi-information using transformer and graph neural network model.
Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Application of Deep Learning in Cancer Prognosis Prediction Model.Technology in cancer research & treatmentPooled it
- [Advances on Postoperative Recurrence Risk Prediction in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Multimodal data analysis reveals asynchronous aging dynamics across female reproductive organs.Nature aging · 2026Article
- CoFormerSurv: Collaborative transformer for multi-omics survival analysis.PLoS computational biology · 2026Article
- Application of deep learning in prognostic prediction of non-small cell lung cancer.Frontiers in cell and developmental biology · 2026Review
- Ablation versus sublobar resection for stage IA non-small cell lung cancer: a multicenter retrospective cohort study using a deep learning model in the ablation group.International journal of surgery (London, England) · 2025Article
- Multimodal radiomics fusion for predicting postoperative recurrence in NSCLC patients.Journal of cancer research and clinical oncology · 2025Article
- A Comprehensive Review on the Application of Artificial Intelligence for Predicting Postsurgical Recurrence Risk in Early-Stage Non-Small Cell Lung Cancer Using Computed Tomography, Positron Emission Tomography, and Clinical Data.Journal of medical radiation sciences · 2025Review
- Multimodal integration of longitudinal noninvasive diagnostics for survival prediction in immunotherapy using deep learning.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia.The oncologist · 2025Article
- Classifying the molecular subtype of breast cancer using vision transformer and convolutional neural network features.Breast cancer research and treatment · 2025Article
- Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine.Frontiers in cell and developmental biology · 2025Review
- Personalized progression modelling and prediction in Parkinson's disease with a novel multi-modal graph approach.NPJ Parkinson's disease · 2024Article
- A Hybrid CNN-Transformer Model for Predicting N Staging and Survival in Non-Small Cell Lung Cancer Patients Based on CT-Scan.Tomography (Ann Arbor, Mich.) · 2024Article
- Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology.Briefings in bioinformatics · 2024Review
- Advancing mortality rate prediction in European population clusters: integrating deep learning and multiscale analysis.Scientific reports · 2024Article
- Multimodal data integration for oncology in the era of deep neural networks: a review.Frontiers in artificial intelligence · 2024Review
- A dual-radiomics model for overall survival prediction in early-stage NSCLC patient using pre-treatment CT images.Frontiers in oncology · 2024Article
- Review
- Comparison between vision transformers and convolutional neural networks to predict non-small lung cancer recurrence.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We proposed a population graph with Transformer-generated and clinical features for the purpose of predicting overall survival (OS) and recurrence-free survival (RFS) for patients with early stage non-small cell lung carcinomas and to compare this model with traditional models. Methods: The study included 1705 patients with lung cancer (stages I and II), and a public data set for external validation (n=127). We proposed a graph with edges representing non-imaging patient characteristics and nodes representing imaging tumour region characteristics generated by a pretrained Vision Transformer. The model was compared with a TNM model and a ResNet-Graph model. To evaluate the models' performance, the area under the receiver operator characteristic curve (ROC-AUC) was calculated for both OS and RFS prediction. The Kaplan-Meier method was used to generate prognostic and survival estimates for low- and high-risk groups, along with net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis. An additional subanalysis was conducted to examine the relationship between clinical data and imaging features associated with risk prediction. Results: Our model achieved AUC values of 0.785 (95% confidence interval [CI]: 0.716-0.855) and 0.695 (95% CI: 0.603-0.787) on the testing and external data sets for OS prediction, and 0.726 (95% CI: 0.653-0.800) and 0.700 (95% CI: 0.615-0.785) for RFS prediction. Additional survival analyses indicated that our model outperformed the present TNM and ResNet-Graph models in terms of net benefit for survival prediction. Conclusions: Our Transformer-Graph model was effective at predicting survival in patients with early stage lung cancer, which was constructed using both imaging and non-imaging clinical features. Some high-risk patients were distinguishable by using a similarity score function defined by non-imaging characteristics such as age, gender, histology type, and tumour location, while Transformer-generated features demonstrated additional benefits for patients whose non-imaging characteristics were non-discriminatory for survival outcomes. Funding: The study was supported by the National Natural Science Foundation of China (91959126, 8210071009), and Science and Technology Commission of Shanghai Municipality (20XD1403000, 21YF1438200).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.